{"protocolSection":{"identificationModule":{"nctId":"NCT03242915","orgStudyIdInfo":{"id":"UMCC 2017.057"},"secondaryIdInfos":[{"id":"HUM00129169","type":"OTHER","domain":"University of Michigan"}],"organization":{"fullName":"University of Michigan Rogel Cancer Center","class":"OTHER"},"briefTitle":"Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents","officialTitle":"Phase II Study of Pembrolizumab in Combination With Platinum-based Chemotherapy in Nonsmall Cell Lung Cancer Patients With Targetable Genetic Alterations Previously Treated With Appropriate Targeted Agents With Progressive Disease"},"statusModule":{"statusVerifiedDate":"2025-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-10-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-02-20","type":"ACTUAL"},"completionDateStruct":{"date":"2025-02-20","type":"ACTUAL"},"studyFirstSubmitDate":"2017-08-03","studyFirstSubmitQcDate":"2017-08-03","studyFirstPostDateStruct":{"date":"2017-08-08","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-04-03","resultsFirstSubmitQcDate":"2025-05-12","resultsFirstPostDateStruct":{"date":"2025-05-30","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-12","lastUpdatePostDateStruct":{"date":"2025-05-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University of Michigan Rogel Cancer Center","class":"OTHER"},"collaborators":[{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Investigators hypothesize that addition of pembrolizumab will enhance the efficacy of carboplatin and pemetrexed in patients with EGFR-mutation-positive NSCLC, or patients with other genetic alterations, and who have disease progression following appropriate targeted therapies."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":33,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pembrolizumab/Carboplatin/Pemetrexed","type":"EXPERIMENTAL","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks","interventionNames":["Drug: Pembrolizumab","Drug: Carboplatin","Drug: Pemetrexed"]}],"interventions":[{"type":"DRUG","name":"Pembrolizumab","description":"200mg IV every 3 weeks","armGroupLabels":["Pembrolizumab/Carboplatin/Pemetrexed"]},{"type":"DRUG","name":"Carboplatin","description":"AUC 5 IV every 3 weeks","armGroupLabels":["Pembrolizumab/Carboplatin/Pemetrexed"]},{"type":"DRUG","name":"Pemetrexed","description":"500 mg/m\\^2 IV every 3 weeks","armGroupLabels":["Pembrolizumab/Carboplatin/Pemetrexed"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Percentage of Patients That Respond to Treatment","description":"The primary endpoint is Response Rate (RR) defined as the rate of complete and partial response. Complete Response (CR): Disappearance of all non-target lesions. All lymph nodes must be non-pathological in size (\\<10mm short axis). Partial Response (PR): Persistence of one or more non-target lesion(s) but does not qualify for PD. Progressive Disease (PD): Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).","timeFrame":"5.5 years"}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS) Time","description":"PFS is defined as the duration of time from registration to time of progression. Progressive Disease (PD): Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).","timeFrame":"5.5 years"},{"measure":"Overall Survival (OS) Time","description":"Overall survival is defined as the time from registration to time of death. If the patient is lost to follow-up, survival will be censored on the last date the patient was known to be alive.","timeFrame":"5.5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cohort-specific:\n\nCohort 1- EGFR mutation positive NSCLC patients previously treated with appropriate targeted therapy with progressive and measurable disease per RECIST 1.1 criteria tumor.\n\nCohort 2- Other genetically altered NSCLC patients previously treated with appropriate targeted therapy with progressive and measurable tumor.\n\n* Tumor tissue for PD-L1 assessment should be available unless PD-L1 assessment results are already available.\n* Patients should not have received any systemic chemotherapy for advanced NSCLC. Patients who received 1 cycle of systemic chemotherapy for advanced NSCLC while awaiting the results of tumor molecular analysis and subsequently were switched to appropriate targeted therapy will be eligible. Patients who have received neoadjuvant, adjuvant or as part of concurrent chemotherapy and radiation are eligible if they received the chemotherapy 12 months or more before the start of study therapy.\n* ECOG PS 0-1 (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.)\n* Patients should have recovered to ≤ grade 1 from clinically meaningful (example alopecia is not considered clinically meaningful) adverse events related to prior treatments.\n* Patients should be willing and able to provide written informed consent for the trial.\n* Be ≥ 18 years of age on day of signing informed consent.\n* Demonstrate adequate organ function\n* Female subject of childbearing potential should have a negative urine or serum pregnancy within 1 week of enrollment.\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception\n* Male subjects of child bearing potential must agree to use an adequate method of contraception\n\nExclusion Criteria:\n\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. If the half-life of the drug is known then starting therapy 5 half-lives after the end of the last therapy is acceptable.\n* Has a diagnosis of immunodeficiency. Patient should not be of any immunosuppressive therapy or steroids \\> prednisone 10mg/day or its equivalent on the day of the start of therapy.\n* Has a known history of active TB (Bacillus Tuberculosis)\n* Hypersensitivity to pembrolizumab, carboplatin or pemetrexed or any of its excipients.\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n* Has had targeted small molecule therapy, or palliative radiation therapy within 1 week prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.\n* Has a known additional malignancy that is progressing or requires active treatment or the treating physician believes will require therapy within 1 year.\n* Has symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years\n* Has known history of non-infectious pneumonitis that required steroids or has current pneumonitis. Has known history of interstitial lung disease.\n* Has an active infection requiring systemic therapy.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n* Has known active Hepatitis B or Hepatitis C\n* Has received a live vaccine within 30 days of planned start of study therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Gregory Kalemkerian, M.D.","affiliation":"University of Michigan Rogel Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Rush University Medical Center","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"The University of Michigan Comprehensive Cancer Center","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Barbara Ann Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Henry Ford Cancer Institute/Henry Ford Hospital","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Montefiore Cancer Center","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Cleveland Clinic","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Sarah Cannon","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"EGFR+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"},{"id":"FG001","title":"ALK+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"EGFR+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"},{"id":"BG001","title":"ALK+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"33"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"14"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"21"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"27"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"23"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"33"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Patients That Respond to Treatment","description":"The primary endpoint is Response Rate (RR) defined as the rate of complete and partial response. Complete Response (CR): Disappearance of all non-target lesions. All lymph nodes must be non-pathological in size (\\<10mm short axis). Partial Response (PR): Persistence of one or more non-target lesion(s) but does not qualify for PD. Progressive Disease (PD): Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of patients","timeFrame":"5.5 years","groups":[{"id":"OG000","title":"EGFR+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"},{"id":"OG001","title":"ALK+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","lowerLimit":"27","upperLimit":"67"},{"groupId":"OG001","value":"29","lowerLimit":"4","upperLimit":"71"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Time","description":"PFS is defined as the duration of time from registration to time of progression. Progressive Disease (PD): Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"5.5 years","groups":[{"id":"OG000","title":"EGFR+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"},{"id":"OG001","title":"ALK+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"7.2","upperLimit":"16.5"},{"groupId":"OG001","value":"2.9","lowerLimit":"1.1","upperLimit":"NA","comment":"Not evaluable as there were not a sufficient number of events for us to estimate those values"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) Time","description":"Overall survival is defined as the time from registration to time of death. If the patient is lost to follow-up, survival will be censored on the last date the patient was known to be alive.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"5.5 years","groups":[{"id":"OG000","title":"EGFR+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"},{"id":"OG001","title":"ALK+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","lowerLimit":"20.6","upperLimit":"NA","comment":"Not evaluable as there were not a sufficient number of events for us to estimate those values"},{"groupId":"OG001","value":"2.9","lowerLimit":"1.1","upperLimit":"NA","comment":"Not evaluable as there were not a sufficient number of events for us to estimate those values"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"All adverse event data (serious and non-serious) collected from the time of the initial study treatment administration through 30 days (non-serious) and 90 days (serious) after the last dose of study treatment. Up to 2 years for adverse events and serious adverse events. 5.5 years for survival.","eventGroups":[{"id":"EG000","title":"EGFR+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks","deathsNumAffected":24,"deathsNumAtRisk":26,"seriousNumAffected":10,"seriousNumAtRisk":26,"otherNumAffected":26,"otherNumAtRisk":26},{"id":"EG001","title":"ALK+ NSCLC","description":"Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks\n\nPembrolizumab: 200mg IV every 3 weeks\n\nCarboplatin: AUC 5 IV every 3 weeks\n\nPemetrexed: 500 mg/m\\^2 IV every 3 weeks","deathsNumAffected":7,"deathsNumAtRisk":7,"seriousNumAffected":7,"seriousNumAtRisk":7,"otherNumAffected":7,"otherNumAtRisk":7}],"seriousEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":7}]},{"term":"Acidosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Back pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Bronchopulmonary hemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Colonic obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Febrile neutropenia","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Progressive Disease","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypoglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Infections and infestations - Other, specify","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"C. diff","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Pericardial tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":7}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Stroke","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Thromboembolic event","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Upper respiratory infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":11,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Allergic reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Alopecia","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Amnesia","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anemia","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":21,"numAtRisk":26},{"groupId":"EG001","numEvents":18,"numAffected":5,"numAtRisk":7}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Arthralgia","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arthritis","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":8,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Back pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood bilirubin increased","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Blurred vision","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bone pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Bullous dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cholesterol high","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Confusion","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":13,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Creatinine increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":7}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":7}]},{"term":"Dizziness","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysgeusia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysphagia","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Ear and labyrinth disorders - Other, specify","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Tenderness","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ear and labyrinth disorders - Other, specify","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"fullness","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Edema face","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Edema limbs","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Endocrine disorders - Other, specify","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"cold intolerance","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Endocrine disorders - Other, specify","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Diabetes Insipidus","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Epistaxis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Esophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Eye disorders - Other, specify","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Double Vision","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Facial pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fall","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":17,"numAtRisk":26},{"groupId":"EG001","numEvents":10,"numAffected":5,"numAtRisk":7}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Flu like symptoms","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Flushing","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrointestinal disorders - Other, specify","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"polydipsia","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"General disorders and administration site conditions - Other, specify","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Night sweat","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Generalized muscle weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hearing impaired","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hoarseness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hot flashes","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hypercalcemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":7,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hypernatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":26},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":7}]},{"term":"Hypocalcemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":26},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":7}]},{"term":"Hypoglycemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypokalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Hypomagnesemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyponatremia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":14,"numAtRisk":26},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":7}]},{"term":"Hypophosphatemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":7}]},{"term":"Infusion related reaction","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Investigations - Other, specify","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Grey stool","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Investigations - Other, specify","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Low protien","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Investigations - Other, specify","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"TSH increased","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Investigations - Other, specify","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Leucocytosis","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":10,"numAtRisk":26},{"groupId":"EG001","numEvents":11,"numAffected":5,"numAtRisk":7}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Middle ear inflammation","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Mucosal infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Mucositis oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":15,"numAtRisk":26},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":7}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Left eye Cyst","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Excision of left axillary cyst","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nervous system disorders - Other, specify","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Syncope","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nervous system disorders - Other, specify","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Brain fog","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":9,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":7}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":8,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Paresthesia","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":26},{"groupId":"EG001","numEvents":7,"numAffected":2,"numAtRisk":7}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Rash acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Respiratory, thoracic and mediastinal disorders - Other, specify","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"tachypnea","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Respiratory, thoracic and mediastinal disorders - Other, specify","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Dysphonia","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinus pain","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":26},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":7}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin and subcutaneous tissue disorders - Other, specify","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Rash NOS","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin hyperpigmentation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin ulceration","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sore throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":26},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":7}]},{"term":"Upper respiratory infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary frequency","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vaginal discharge","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":7}]},{"term":"Watering eyes","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight gain","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight loss","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":26},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":7}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":26},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":44,"numAffected":15,"numAtRisk":26},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"* Participating Sites agree not to publish or publicly present the Study Data or Study Results until Michigan or Michigan's Principal Investigator have first Published the Study Data or Study Results\n* All Study Data and Results generated by the Participating Site will be owned by Participating Site\n* Sponsors have the right to review and comment on any Public Presentation as defined by the contract\n* Other limitations outline within the contract"},"pointOfContact":{"title":"University of Michigan Rogel Cancer Center ClinicalTrials.gov Admin","organization":"University of Michigan Rogel Cancer Center","email":"ClinicalTrialsgov_CCAdmin@umich.edu","phone":"734-936-9499"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2021-05-03","uploadDate":"2025-04-02T09:16","filename":"Prot_SAP_000.pdf","size":780687},{"typeAbbrev":"ICF","hasProtocol":false,"hasSap":false,"hasIcf":true,"label":"Informed Consent Form","date":"2021-09-21","uploadDate":"2025-04-02T09:17","filename":"ICF_001.pdf","size":221854}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-04-23","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}